Sign In
Buy ARGX
$813.14
+10.97 (+1.37%)
At Close: Jun 03, 2026
argenx to Present at Goldman Sachs 45th Annual Global Healthcare Conference
01:00am, Tuesday, 04'th Jun 2024
June 4, 2024 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today an
argenx SE (ARGX) Q1 2024 Earnings Call Transcript
04:39pm, Thursday, 09'th May 2024
argenx SE (NASDAQ:ARGX ) Q1 2024 Earnings Conference Call May 9, 2024 8:30 AM ET Company Participants Beth DelGiacco - Vice President, Global Head of Corporate Communications and Investor Relations Ti
argenx Reports First Quarter 2024 Financial Results and Provides Business Update
01:00am, Thursday, 09'th May 2024
$398 million in first quarter global net product sales FDA review ongoing for CIDP sBLA with PDUFA target action date of June 21, 2024 On track to submit filing for pre-filled syringe (PFS) in second
Is a Surprise Coming for argenx (ARGX) This Earnings Season?
12:00pm, Wednesday, 08'th May 2024
argenx (ARGX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
argenx announces results of Annual General Meeting of Shareholders
05:30pm, Tuesday, 07'th May 2024
May 7, 2024 – 5:30pm ET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune di
argenx: Innovation Over Losses In Autoimmune Arena
04:02am, Tuesday, 07'th May 2024
argenx stock has decreased by 22% since the last evaluation, reflecting operational challenges and market conditions. The company is facing competition in the clinic, particularly from Immunovant's IM
argenx to Present at BofA Securities 2024 Health Care Conference
01:00am, Tuesday, 07'th May 2024
May 7, 2024 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today ann
argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024
01:00am, Thursday, 02'nd May 2024
May 2, 2024 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today ann
GSK Gears Up for Q1 Earnings: Here's What to Expect
02:21pm, Tuesday, 23'rd Apr 2024
We expect GSK's specialty products like Arexvy, Cabenuva, Juluca, Dovato, Nucala, Trelegy Ellipta and Shingrix to drive first-quarter sales performance.
ADHERE data show VYVGART ® Hytrulo has potential to be first advancement for CIDP patients in 30 years
argenx Advances Clinical Development of Efgartigimod in Primary Sjogren's Disease
02:00am, Wednesday, 27'th Mar 2024
RHO study supports proof-of-concept in primary Sjogren's disease Decision informed by favorable safety profile and consistency across efficacy and biomarker measures March 27, 2024, 7:00 AM CET Amster
argenx Announces Annual General Meeting of Shareholders on May 7, 2024
04:00pm, Tuesday, 26'th Mar 2024
March 26, 2024 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, tod
argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia
02:00am, Tuesday, 26'th Mar 2024
VYVGART ® now approved in Japan for both generalized myasthenia gravis and primary immune thrombocytopenia (ITP)
Why Argenx's (ARGX) Stock Price Moved Up 11% on Thursday
11:31am, Friday, 22'nd Mar 2024
Argenx (ARGX) surges after a Japanese rival posted disappointing results from a late-stage study on its investigational drug for generalized myasthenia gravis.
Argenx (ARGX) Moves 11.2% Higher: Will This Strength Last?
08:51am, Friday, 22'nd Mar 2024
Argenx (ARGX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength dow
